Genetic polymorphisms and risk of metabolic syndrome in schizophrenic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20231114005

Enrollment

200

Registered

2023-11-14

Start date

2014-03-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia and related disorders metabolic syndrome schizophrenia, metabolic syndrome

Interventions

schizophrenic patients receiving antipsychotics

Basic Science

schizophrenic patients

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. age 18 years or older 2. diagnosis of schizophrenia and related disorders (ICD10 diagnosis is F20-F29) 3. has continuously received antipsychotics for the past 6 months

Exclusion criteria

Exclusion criteria: 1. diagnosis of diabetes, hypertension, dyslipidemia, cardiac disease, thyroid disorders, eating disorders or are receiving medications for these conditions before starting antipsychotics 2. pregnancy or breastfeeding 3. receiving mood stabilizers such as lithium and valproate

Design outcomes

Primary

Measure	Time frame
metabolic syndrome at enrollment metabolic syndrome criteria	—

Secondary

Measure	Time frame
Treatment adherence 1 month End-Stage Kidney Disease Adherence Questionnaire (ESRD-AQ)	—

Countries

Thailand

Contacts

Public ContactNattinee Jantaratnotai

Faculty of Science, Mahidol University

nattinee.jan@mahidol.ac.th022015646

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026